Long COVID

Neda Akhtar Hasan, Rachael Rogers, Emma Tucker, Emily Fraser
{"title":"Long COVID","authors":"Neda Akhtar Hasan,&nbsp;Rachael Rogers,&nbsp;Emma Tucker,&nbsp;Emily Fraser","doi":"10.1016/j.mpmed.2024.12.007","DOIUrl":null,"url":null,"abstract":"<div><div>The name ‘long COVID’ was first coined by patients struggling with prolonged symptoms after coronavirus disease (COVID-19) infection. It emerged formally as a clinical entity early in the COVID pandemic, and although hospitalization from the virus has dramatically declined, the incidence of long COVID remains high, affecting an estimated 2 million people in the UK in 2024 according to the Office for National Statistics. Symptoms are diverse, can fluctuate, vary in nature and emerge after mild or severe infection. Fatigue, cognitive dysfunction (brain fog) and breathlessness are major symptoms, although many more are described. These symptoms often impact daily functioning and can limit a return to work. The condition is heterogeneous and the pathophysiological mechanisms remain elusive; however, they are complex, multifaceted and likely to overlap with myalgic encephalitis/chronic fatigue syndrome. There are no currently available approved pharmacological treatments and management is supportive, focusing around rehabilitation strategies. This chapter provides an overview of the presentation, diagnosis and management of long COVID, highlighting the importance of a holistic, multidisciplinary approach to care.</div></div>","PeriodicalId":74157,"journal":{"name":"Medicine (Abingdon, England : UK ed.)","volume":"53 3","pages":"Pages 166-171"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine (Abingdon, England : UK ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1357303924003050","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The name ‘long COVID’ was first coined by patients struggling with prolonged symptoms after coronavirus disease (COVID-19) infection. It emerged formally as a clinical entity early in the COVID pandemic, and although hospitalization from the virus has dramatically declined, the incidence of long COVID remains high, affecting an estimated 2 million people in the UK in 2024 according to the Office for National Statistics. Symptoms are diverse, can fluctuate, vary in nature and emerge after mild or severe infection. Fatigue, cognitive dysfunction (brain fog) and breathlessness are major symptoms, although many more are described. These symptoms often impact daily functioning and can limit a return to work. The condition is heterogeneous and the pathophysiological mechanisms remain elusive; however, they are complex, multifaceted and likely to overlap with myalgic encephalitis/chronic fatigue syndrome. There are no currently available approved pharmacological treatments and management is supportive, focusing around rehabilitation strategies. This chapter provides an overview of the presentation, diagnosis and management of long COVID, highlighting the importance of a holistic, multidisciplinary approach to care.
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信